Evotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.
Confo Therapeutics closes €60m Series B financing
Latest NewsBelgian GPCR specialist Confo Therapeutics NV has raised €60m in an Series B financing round led by Ackermans & van Haaren to advance clinical development of two clinical programmes and preclinical candidates to treat rare endocrine diseases and obesity.
AC Immune bags FDA fast track designation
Latest NewsSwiss AC Immune and its partner Janssen Pharmaceuticals Inc have been granted FDA Fast Track Designation for their active anti-pTau vaccine ACI-35.030/JNJ-2056 to treat Alzheimer’s disease.
New targets for incurable blood cancer
Latest NewsA research consortium led by Charité in Berlin has found a protein pattern in 100 patients with the common blood cancer multiple myeloma and 38 healthy controls that independently identifies a poor prognosis and provides new targets for treating the incurable disease.
SynaptixBio Ltd and Evotec SE expand collaboration
Latest NewsEvotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.
Von der Leyen: no mention of biotechnology
Latest NewsIn view of her confirmation as EU Commission President, biotech associations have reminded Ursula von der Leyen of her promise to strategically promote the sector with an EU Biotech Act 2025.
Scientists prevent transplant rejection
Latest NewsScientists at Hannover Medical School (MHH) have genetically engineered pig lungs in such a way that immunosuppressants could be reduced during transplants.
New Chief Scientific Officer
AppointmentsCambridge-based Mogrify Ltd announces the appointment of Dr. Jonathan Appleby as Chief Scientific Officer.
SOTIO partners with Biocytogen to expand ADC pipeline
Latest NewsCzech Sotio Biotech has inked an R&D and licence option agreement with Chinese antibody maker Biocytogen.
Draupnir Bio ApS raises further equity
Latest NewsTargeted protein degradation Draupnir Bio Aps has raised further €12m in an equitiy investment to advance its preclinical pipeline.
CordenPharma invests €900m in peptide patform expansion
Latest NewsCordenPharma is making a record investment of about €900m over the next three years in expanding its peptide platform, both at its Colorado, US site and in Europe.